Skip to main content

The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

AbbVie’s Januns kinase (“JAK”) inhibitor drug, Rinvoq, has been approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of moderate to severe rheumatoid arthritis (“RA”). In 2020, AbbVie sought regulatory approval to expand the indications for Rinvoq.

On June 25, 2021, AbbVie disclosed that the FDA would not complete its review of several of the expanded treatment indications for Rinvoq within the previously-announced timeframe due to its ongoing evaluation of safety concerns associated with other JAK inhibitor drugs.

On this news, AbbVie’s common stock fell $1.76, or 1.5%, to close at $112.98 per share on June 25, 2021, thereby injuring investors.

Then, on September 1, 2021, the FDA announced that the safety trials for other JAK inhibitor drugs had established an increased risk of serious adverse events, even with low doses, and determined that new and updated warnings would be required for those drugs as well as for Rinvoq, as it shares “similar mechanisms of action” and “may have similar risks.” The FDA also disclosed that it would further limit approved indications for Rinvoq as a result of safety concerns.

On this news, AbbVie’s common stock fell $8.51, or 7%, to close at $112.27 per share on September 1, 2021, thereby injuring investors further.

Follow us for updates on Twitter:

If you purchased AbbVie securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to, or visit our website at If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.